AI Tokens
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Short-term (Operating) Activity Ratios
Quarterly Data

Microsoft Excel

Short-term Activity Ratios (Summary)

Turnover Ratios

Average No. Days

Gilead Sciences Inc., short-term (operating) activity ratios (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Turnover Ratios
Inventory turnover 3.28 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Receivables turnover 6.14 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Payables turnover 6.66 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Working capital turnover 6.76 10.20 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Average No. Days
Average inventory processing period 111 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Add: Average receivable collection period 59 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Operating cycle 170 177 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Less: Average payables payment period 55 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Cash conversion cycle 115 137 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).


The operational activity ratios indicate a general decline in efficiency regarding asset utilization and cash flow velocity over the analyzed period. The most significant trend is the expansion of the operating and cash conversion cycles, primarily driven by a slowdown in inventory turnover.

Inventory Management
Inventory turnover has exhibited a gradual downward trend, decreasing from 4.50 in early 2022 to 3.28 by September 2026. Correspondingly, the average inventory processing period has lengthened from 81 days to 111 days. This suggests a slower movement of stock and an increase in the duration that capital remains tied up in inventory.
Receivables Management
Receivables turnover has remained relatively stable, fluctuating within a range of 5.60 to 7.18. The average receivable collection period has shown minimal volatility, generally oscillating between 51 and 65 days. This indicates a consistent and predictable approach to credit collection and revenue realization.
Payables and Working Capital
Payables turnover shows significant volatility, with sharp fluctuations between a high of 12.57 and a low of 6.25. The average payables payment period varies widely, ranging from 29 to 58 days, suggesting inconsistent payment strategies or shifting vendor terms. Working capital turnover has been highly erratic, characterized by extreme spikes—most notably reaching 84.15 in June 2023—followed by a return to lower levels, indicating periods of significant volatility in the relationship between current assets, liabilities, and revenue.
Operational Cycles
The operating cycle has extended from 132 days in March 2022 to 170 days by September 2026, reflecting the cumulative impact of slower inventory turnover. The cash conversion cycle has followed a similar upward trajectory, rising from 100 days to 115 days, with a peak of 143 days in June 2024. This extension signifies that the company takes longer to convert its investments in inventory and receivables back into cash.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Inventory Turnover

Gilead Sciences Inc., inventory turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of goods sold 1,571 1,579 1,445 1,624 1,569 1,501 1,540 1,581 1,574 1,544 1,552 2,090 1,565 1,442 1,401 1,396 1,395 1,442 1,424
Inventories 1,896 1,953 1,914 1,774 1,785 1,825 1,759 1,710 1,869 2,026 1,853 1,787 1,663 1,633 1,576 1,507 1,463 1,494 1,482
Short-term Activity Ratio
Inventory turnover1 3.28 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Benchmarks
Inventory Turnover, Competitors2
AbbVie Inc. 3.27 3.58 3.65 3.68 3.65 3.42 3.71 4.04 4.09 4.86 4.83 4.98 4.74 4.30 4.53 4.87 5.54 4.99 4.96
Amgen Inc. 1.77 1.87 1.91 1.93 1.92 1.88 1.88 1.84 1.75 1.42 1.14 0.89 1.41 1.38 1.31 1.30 1.34 1.40 1.48
Bristol-Myers Squibb Co. 5.69 5.36 5.20 5.18 5.31 5.18 5.28 5.46 3.57 3.72 3.70 4.02 4.33 4.39 3.93 4.33 4.77 4.59 4.55
Danaher Corp. 3.38 3.20 3.90 4.04 3.67 3.60 3.79 4.15 3.60 3.59 3.73 3.80 3.53 3.58 3.50 4.03 3.80 3.71 3.87
Eli Lilly & Co. 0.78 0.79 0.85 0.80 0.83 0.84 0.96 1.11 1.05 1.16 1.17 1.23 1.40 1.37 1.36 1.54 1.86 1.79 1.93
Johnson & Johnson 2.10 2.08 2.13 2.13 2.08 2.17 2.24 2.21 2.15 2.20 2.32 2.37 2.46 2.23 2.36 2.49 2.68 2.69 2.77
Merck & Co. Inc. 3.09 2.90 2.65 2.46 2.27 2.25 2.43 2.49 2.45 2.39 2.42 2.54 2.63 2.66 2.72 2.95 3.10 3.06 2.74
Pfizer Inc. 1.69 1.72 1.57 1.51 1.46 1.52 1.60 1.65 1.66 2.05 2.15 2.45 2.65 2.31 3.07 3.82 3.62 3.66 3.67
Regeneron Pharmaceuticals Inc. 0.83 0.76 0.74 0.66 0.64 0.64 0.63 0.64 0.64 0.65 0.66 0.70 0.72 0.69 0.67 0.65 0.83 0.96 1.27
Thermo Fisher Scientific Inc. 4.94 4.87 4.87 4.85 4.47 4.57 4.82 5.06 4.62 4.83 4.93 5.06 4.83 4.64 4.62 4.60 4.29 4.03 3.87
Vertex Pharmaceuticals Inc. 0.83 1.00 0.95 0.98 0.99 1.06 1.14 1.27 1.37 1.53 1.65 1.71 1.71 1.90 2.06 2.35 2.69 2.70 2.83

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Inventory turnover = (Cost of goods soldQ3 2026 + Cost of goods soldQ2 2026 + Cost of goods soldQ1 2026 + Cost of goods soldQ4 2025) ÷ Inventories
= (1,571 + 1,579 + 1,445 + 1,624) ÷ 1,896 = 3.28

2 Click competitor name to see calculations.


The analysis of operating activity reveals a consistent long-term decline in inventory turnover efficiency. Over the period from March 2022 to September 2026, the turnover ratio transitioned from a peak of 4.71 to a low of 3.18, signaling a slowdown in the rate at which inventory is sold and replaced.

Inventory Level Trends
Inventory balances exhibited a general upward trajectory, increasing from 1,482 million USD in March 2022 to a peak of 2,026 million USD in June 2024. While there was a temporary correction toward the end of 2024, inventory levels remained elevated throughout 2025 and 2026, consistently staying above 1,700 million USD. This growth in stored assets without a proportional increase in sales volume contributed to the overall reduction in turnover efficiency.
Cost of Goods Sold (COGS) Volatility
The cost of goods sold remained relatively stable for much of the period, typically fluctuating between 1,400 million USD and 1,600 million USD per quarter. A significant outlier occurred in December 2023, where COGS spiked to 2,090 million USD. This surge provided a temporary boost to the turnover ratio during that specific quarter, though it did not alter the broader downward trend.
Inventory Turnover Ratio Performance
The inventory turnover ratio can be divided into three distinct phases. Initially, from March 2022 to September 2022, the company maintained high efficiency with ratios between 4.50 and 4.71. A period of deterioration followed between December 2022 and June 2023, where the ratio dropped toward the 3.45 range. The final phase, spanning 2025 and 2026, shows a further decline to a baseline between 3.18 and 3.28, indicating that inventory is held longer before being converted into sales.

The convergence of rising inventory levels and stagnant cost of goods sold indicates a decreasing operational velocity. The transition from a turnover ratio of 4.71 to 3.28 suggests that the company is carrying more stock relative to its sales requirements than it did at the start of the analyzed period.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Receivables Turnover

Gilead Sciences Inc., receivables turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Product sales 8,289 7,627 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534
Accounts receivable, net 5,007 5,055 4,741 4,913 5,095 4,781 4,388 4,420 4,587 4,663 4,669 4,660 4,790 4,229 4,162 4,777 4,354 4,118 3,787
Short-term Activity Ratio
Receivables turnover1 6.14 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Benchmarks
Receivables Turnover, Competitors2
AbbVie Inc. 4.89 4.66 5.03 4.86 4.67 4.62 4.60 5.16 4.84 4.69 4.55 4.87 4.83 4.88 4.95 5.16 5.38 5.10 5.29
Amgen Inc. 3.57 3.55 3.88 3.67 4.06 3.85 4.03 4.72 4.26 4.26 4.16 3.70 4.17 4.34 4.34 4.46 4.60 4.62 4.81
Danaher Corp. 6.21 6.33 6.49 6.28 6.46 6.74 6.79 6.75 6.77 7.15 7.02 6.09 6.15 6.64 6.89 6.40 7.09 6.81 6.87
Eli Lilly & Co. 3.91 3.97 3.92 3.67 3.69 3.76 4.07 4.09 3.97 3.53 4.56 3.75 3.93 3.93 3.68 4.14 4.35 4.57 4.64
Johnson & Johnson 5.23 5.14 5.44 5.48 5.23 5.08 5.58 5.98 5.42 5.48 5.73 5.73 5.91 5.36 5.65 5.88 6.04 5.92 6.08
Merck & Co. Inc. 5.29 5.30 5.39 5.52 5.30 5.37 5.92 6.24 5.55 5.37 5.40 5.81 5.71 5.29 5.56 6.27 6.22 5.93 5.49
Pfizer Inc. 4.48 5.10 5.03 5.27 4.40 5.29 5.27 5.55 4.18 4.93 5.09 5.33 6.25 7.66 7.57 9.16 6.21 6.68 6.99
Regeneron Pharmaceuticals Inc. 2.23 2.37 2.60 2.50 2.51 2.53 2.53 2.29 2.27 2.36 2.51 2.31 2.35 2.47 2.42 2.28 2.47 2.76 3.41
Thermo Fisher Scientific Inc. 4.92 4.90 4.91 5.01 4.91 5.03 5.07 5.23 5.13 5.33 5.36 5.21 5.19 5.43 5.53 5.53 5.76 5.53 5.21
Vertex Pharmaceuticals Inc. 5.60 5.90 6.12 5.85 6.02 6.03 6.15 6.85 6.07 6.24 5.68 6.31 6.27 6.11 5.95 6.19 6.28 6.26 6.15

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Receivables turnover = (Product salesQ3 2026 + Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025) ÷ Accounts receivable, net
= (8,289 + 7,627 + 6,946 + 7,903) ÷ 5,007 = 6.14

2 Click competitor name to see calculations.


The analysis of the receivables turnover ratio reveals a period of volatility characterized by cyclical fluctuations rather than a linear trend. The ratio, which measures the efficiency of converting accounts receivable into cash, peaked at 7.18 in March 2022 and reached its lowest point of 5.60 in September 2025, ending the period at 6.14 in September 2026.

Correlation Between Sales and Receivables
Product sales exhibited a general upward trajectory over the analyzed period, growing from 6,534 million USD in March 2022 to 8,289 million USD by September 2026. During this same interval, net accounts receivable increased from 3,787 million USD to 5,007 million USD. The fluctuations in the turnover ratio are primarily driven by the rate at which receivables grew relative to sales. For instance, the decline in the ratio during 2022 coincided with a sharp increase in net accounts receivable that outpaced the growth in product sales.
Efficiency Cycles and Troughs
Three distinct periods of declining efficiency are observable. The first occurred between March 2022 and December 2022, where the ratio dropped from 7.18 to 5.65. A second dip was noted in September 2023 (5.68), and a third, more pronounced decline reached a minimum of 5.60 in September 2025. These troughs typically correspond with quarters where accounts receivable balances expanded significantly relative to the quarterly sales volume, suggesting temporary delays in collections or changes in credit terms.
Recovery Patterns
Periods of recovery in the turnover ratio indicate improved collection efficiency or a reduction in outstanding receivables. A notable recovery occurred between December 2023 and December 2024, with the ratio climbing from 5.78 to 6.47. This improvement was supported by a reduction in net accounts receivable from 4,660 million USD to 4,420 million USD despite steady product sales, indicating a more aggressive or effective collection process during that fiscal window.
Long-term Operating Trend
Comparing the starting point of 7.18 in March 2022 to the ending point of 6.14 in September 2026 suggests a moderate decrease in overall receivables turnover efficiency over the long term. While product sales grew by approximately 27%, the net accounts receivable balance grew by approximately 32%, resulting in a slightly lower turnover ratio at the end of the period than at the beginning.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Payables Turnover

Gilead Sciences Inc., payables turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Cost of goods sold 1,571 1,579 1,445 1,624 1,569 1,501 1,540 1,581 1,574 1,544 1,552 2,090 1,565 1,442 1,401 1,396 1,395 1,442 1,424
Accounts payable 934 674 645 715 808 582 737 833 903 537 622 550 586 622 627 905 614 565 583
Short-term Activity Ratio
Payables turnover1 6.66 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Benchmarks
Payables Turnover, Competitors2
Amgen Inc. 3.84 4.05 4.02 5.09 4.29 4.12 5.25 6.74 5.99 5.01 6.10 5.32 5.22 5.67 4.97 4.08 5.30 5.09 4.65
Bristol-Myers Squibb Co. 3.33 3.53 3.38 3.90 3.42 2.61 3.52 3.88 3.43 3.05 3.12 3.28 3.75 3.38 3.20 3.33 3.82 3.41 3.25
Danaher Corp. 6.09 5.72 5.68 5.45 5.78 5.62 5.57 5.52 6.04 5.84 5.88 5.58 5.63 5.82 5.68 5.45 5.61 5.00 5.04
Eli Lilly & Co. 2.44 2.16 2.47 2.05 2.37 2.27 2.61 2.61 2.70 2.56 2.88 2.73 2.81 2.65 3.07 3.43 4.24 4.21 5.24
Johnson & Johnson 3.46 3.41 2.96 2.52 3.06 3.07 2.97 2.66 3.03 3.03 3.23 2.76 3.29 2.75 3.05 2.66 3.08 3.15 3.26
Merck & Co. Inc. 3.78 4.70 4.44 3.72 3.53 3.82 3.98 3.72 4.26 4.39 4.48 4.11 4.59 4.58 4.34 4.08 5.16 4.86 4.25
Pfizer Inc. 4.16 3.73 3.72 3.07 3.32 3.44 3.30 3.17 3.67 4.60 4.19 3.72 5.07 3.92 4.78 5.04 5.49 6.17 6.66
Regeneron Pharmaceuticals Inc. 2.11 2.03 2.24 2.24 2.30 2.83 2.84 2.50 3.87 3.32 2.67 2.99 3.43 3.14 2.69 2.65 3.74 4.00 5.39
Thermo Fisher Scientific Inc. 9.04 8.39 8.00 7.27 8.23 8.53 8.25 8.18 9.63 9.85 9.91 8.97 10.41 10.82 9.35 7.67 9.93 8.84 7.96
Vertex Pharmaceuticals Inc. 3.97 4.10 3.44 3.58 3.83 3.59 3.49 3.71 3.73 4.27 3.81 3.46 3.13 3.16 3.41 3.55 8.23 5.01 5.52

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Payables turnover = (Cost of goods soldQ3 2026 + Cost of goods soldQ2 2026 + Cost of goods soldQ1 2026 + Cost of goods soldQ4 2025) ÷ Accounts payable
= (1,571 + 1,579 + 1,445 + 1,624) ÷ 934 = 6.66

2 Click competitor name to see calculations.


The analysis of payables turnover reveals a volatile trend characterized by periodic declines that correlate closely with spikes in accounts payable balances. The ratio fluctuates between a high of 12.57 and a low of 6.25, indicating inconsistent cycles in the settlement of obligations to suppliers over the observed period.

Payables Turnover Volatility
A pattern of cyclical instability is evident. The ratio maintained relative stability between March 2022 and September 2022, followed by a sharp contraction to 6.25 in December 2022. While the ratio recovered to 11.81 by December 2023 and reached its peak of 12.57 in June 2024, it experienced subsequent declines in September 2024 (7.49) and September 2026 (6.66).
Impact of Accounts Payable Fluctuations
Significant drops in the turnover ratio are directly tied to substantial increases in accounts payable. Specifically, the lows observed in December 2022, September 2024, and September 2026 correspond with payables balances rising to 905 million, 903 million, and 934 million USD, respectively. These spikes suggest periods where the company extended its payment terms or experienced an accumulation of short-term liabilities, thereby slowing the turnover rate.
Cost of Goods Sold (COGS) Correlation
Cost of goods sold remained relatively stable, generally ranging between 1.4 billion and 1.6 billion USD, with a notable outlier of 2.09 billion USD in December 2023. Despite this spike in costs, the payables turnover ratio actually increased to 11.81 during that quarter, indicating that the increase in COGS was not matched by a proportional increase in accounts payable, leading to a more rapid turnover of liabilities.
Operational Efficiency Insights
The highest level of efficiency in clearing payables occurred in June 2024, where the ratio peaked at 12.57. Conversely, the recurring dips toward the 6.0 to 7.0 range suggest a periodic strategic or operational shift toward utilizing supplier credit for working capital management, effectively delaying cash outflows at specific quarterly intervals.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Working Capital Turnover

Gilead Sciences Inc., working capital turnover calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data (US$ in millions)
Current assets 16,553 13,945 18,641 18,342 17,874 14,718 16,901 19,173 14,779 12,317 14,041 16,085 15,980 14,287 13,456 14,443 13,554 13,175 12,629
Less: Current liabilities 12,002 11,020 9,476 11,813 12,298 11,189 12,344 12,004 11,725 10,781 13,015 11,280 11,945 13,964 10,528 11,237 10,423 9,220 8,558
Working capital 4,551 2,925 9,165 6,529 5,576 3,529 4,557 7,169 3,054 1,536 1,026 4,805 4,035 323 2,928 3,206 3,131 3,955 4,071
 
Product sales 8,289 7,627 6,946 7,903 7,345 7,054 6,613 7,536 7,515 6,912 6,647 7,070 6,994 6,564 6,306 7,332 6,978 6,138 6,534
Short-term Activity Ratio
Working capital turnover1 6.76 10.20 3.19 4.43 5.12 8.14 6.27 3.99 9.22 17.98 26.58 5.61 6.74 84.15 9.14 8.42 8.56 6.87 6.68
Benchmarks
Working Capital Turnover, Competitors2
AbbVie Inc. — — — — — — — — — — — — — — — — — — —
Amgen Inc. 3.32 3.83 5.44 9.85 5.66 5.35 8.36 5.40 4.83 5.19 3.39 2.25 0.81 0.84 0.82 3.82 2.52 3.67 4.34
Bristol-Myers Squibb Co. 4.40 4.81 5.84 7.83 6.20 8.09 6.87 7.79 8.49 12.50 15.56 4.60 10.47 5.53 5.55 8.30 5.75 4.92 6.24
Danaher Corp. 4.46 4.76 3.83 4.13 7.39 5.71 8.27 8.85 8.73 8.10 3.60 4.22 2.18 3.08 3.81 4.20 5.00 5.43 5.91
Eli Lilly & Co. 4.73 4.71 3.97 3.19 2.71 4.92 4.38 10.32 6.06 12.62 5.45 — 31.79 12.21 5.77 31.84 14.71 19.45 8.19
Johnson & Johnson 111.11 20.07 66.14 62.88 24.63 284.99 6.10 15.94 58.86 22.29 10.35 11.81 9.37 14.06 23.02 — 4.88 5.02 5.57
Merck & Co. Inc. 6.64 7.44 8.15 4.28 3.39 5.77 6.19 6.19 5.86 5.14 9.68 9.29 6.69 8.86 5.63 5.16 5.58 6.39 6.09
Pfizer Inc. 4.79 7.31 7.47 10.58 6.08 10.68 6.64 8.64 5,036.00 — 29.17 — 1.62 2.03 6.89 11.00 3.83 5.05 6.10
Regeneron Pharmaceuticals Inc. 1.16 1.20 1.14 1.05 1.05 1.08 1.01 0.97 0.88 0.87 0.86 0.82 0.87 0.92 0.90 0.96 1.09 1.14 1.46
Thermo Fisher Scientific Inc. 4.14 5.59 5.87 3.30 5.90 3.64 4.20 4.87 4.61 3.96 4.38 4.05 4.86 7.40 10.13 5.46 5.40 6.03 6.13
Vertex Pharmaceuticals Inc. 1.94 1.46 1.56 1.64 1.92 1.82 1.78 1.83 1.82 1.92 1.07 0.93 0.87 0.90 0.93 0.85 0.90 0.93 0.97

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Working capital turnover = (Product salesQ3 2026 + Product salesQ2 2026 + Product salesQ1 2026 + Product salesQ4 2025) ÷ Working capital
= (8,289 + 7,627 + 6,946 + 7,903) ÷ 4,551 = 6.76

2 Click competitor name to see calculations.


The analysis of operating activity indicates a period of significant volatility in working capital management, contrasting with a steady and gradual increase in product sales. While revenue streams demonstrate consistent growth, the working capital turnover ratio fluctuates sharply, reflecting instability in the relationship between current assets and current liabilities.

Product Sales Performance
Revenue from product sales shows a general upward trajectory, rising from 6,534 million USD in March 2022 to 8,289 million USD by September 2026. This growth is characterized by moderate quarterly oscillations but lacks the extreme variance observed in the company's short-term asset and liability positions.
Working Capital Volatility
Working capital levels exhibit erratic movements throughout the analyzed period. A critical contraction occurred in June 2023, where working capital dropped to 323 million USD. This was followed by a series of expansions, peaking at 9,165 million USD in March 2026, before sharply declining again to 2,925 million USD in June 2026. These swings suggest aggressive changes in short-term financing or significant shifts in inventory and receivables management.
Working Capital Turnover Dynamics
The turnover ratio reflects the impact of working capital volatility. An exceptional peak of 84.15 was recorded in June 2023, directly resulting from the precipitous drop in working capital relative to stable sales. Conversely, as working capital expanded toward the end of the period, the turnover ratio declined, reaching a low of 3.19 in March 2026. This indicates a period of lower operational efficiency in utilizing working capital to generate sales.
Operational Efficiency Trends
Between March 2022 and March 2023, the turnover ratio trended upward from 6.68 to 9.14, suggesting improving efficiency. However, the subsequent years are marked by inconsistency. The sharp recovery of the ratio to 10.20 in June 2026, following the March 2026 low, indicates a rapid reduction in working capital, which mathematically inflates the turnover ratio regardless of underlying sales growth.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Inventory Processing Period

Gilead Sciences Inc., average inventory processing period calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Inventory turnover 3.28 3.18 3.21 3.51 3.47 3.40 3.55 3.66 3.62 3.33 3.59 3.64 3.49 3.45 3.57 3.75 4.71 4.50 4.50
Short-term Activity Ratio (no. days)
Average inventory processing period1 111 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Benchmarks (no. days)
Average Inventory Processing Period, Competitors2
AbbVie Inc. 112 102 100 99 100 107 98 90 89 75 75 73 77 85 81 75 66 73 74
Amgen Inc. 206 195 191 189 190 194 195 199 209 257 321 411 259 265 279 281 272 260 247
Bristol-Myers Squibb Co. 64 68 70 70 69 70 69 67 102 98 99 91 84 83 93 84 76 79 80
Danaher Corp. 108 114 94 90 99 101 96 88 101 102 98 96 104 102 104 91 96 98 94
Eli Lilly & Co. 469 463 428 454 441 435 379 329 349 316 312 298 261 267 268 237 196 204 189
Johnson & Johnson 174 176 172 171 176 168 163 165 169 166 158 154 149 164 155 147 136 136 132
Merck & Co. Inc. 118 126 138 148 160 162 150 147 149 153 151 144 139 137 134 124 118 119 133
Pfizer Inc. 216 212 232 242 251 239 229 222 219 178 170 149 138 158 119 95 101 100 99
Regeneron Pharmaceuticals Inc. 439 479 491 556 571 570 582 572 573 562 553 519 508 532 549 562 440 379 287
Thermo Fisher Scientific Inc. 74 75 75 75 82 80 76 72 79 76 74 72 76 79 79 79 85 91 94
Vertex Pharmaceuticals Inc. 437 365 384 373 369 345 320 287 267 238 222 214 213 192 177 156 136 135 129

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ 3.28 = 111

2 Click competitor name to see calculations.


An analysis of the short-term operating activity indicators reveals a general decline in inventory management efficiency from March 2022 through September 2026. The inverse relationship between the inventory turnover ratio and the average inventory processing period demonstrates a consistent trend toward longer holding cycles and slower inventory liquidation.

Inventory Turnover Ratio
The inventory turnover ratio experienced a peak of 4.71 in September 2022 before entering a period of gradual decline. Following this peak, the ratio dropped significantly to 3.75 by December 2022 and remained largely within the 3.33 to 3.66 range throughout 2023 and 2024. A further deterioration in turnover efficiency is observed in 2026, where the ratio reached its lowest points, dipping to 3.18 in June 2026 and ending at 3.28 in September 2026.
Average Inventory Processing Period
The average inventory processing period shows a corresponding upward trend, indicating that goods are remaining in inventory for longer durations. The period began at 81 days in the first half of 2022 and escalated to 97 days by December 2022. Throughout 2023 and 2024, the processing period fluctuated primarily between 100 and 110 days. The most pronounced extension of the cycle occurred in the first half of 2026, peaking at 115 days in June 2026 before settling at 111 days by September 2026.
Operational Trend Analysis
The data suggests a systemic shift in operating activity. The transition from a processing period of approximately 80 days to a period exceeding 110 days represents a significant increase in the time capital is tied up in inventory. The stability observed between 2023 and 2025 was followed by a noticeable decrease in efficiency during the 2026 period, signaling a potential slowdown in inventory throughput or a strategic increase in safety stock levels.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Receivable Collection Period

Gilead Sciences Inc., average receivable collection period calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Receivables turnover 6.14 5.90 6.17 5.89 5.60 6.01 6.51 6.47 6.14 5.92 5.84 5.78 5.68 6.43 6.43 5.65 6.16 6.60 7.18
Short-term Activity Ratio (no. days)
Average receivable collection period1 59 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Benchmarks (no. days)
Average Receivable Collection Period, Competitors2
AbbVie Inc. 75 78 73 75 78 79 79 71 75 78 80 75 76 75 74 71 68 72 69
Amgen Inc. 102 103 94 99 90 95 91 77 86 86 88 99 88 84 84 82 79 79 76
Danaher Corp. 59 58 56 58 56 54 54 54 54 51 52 60 59 55 53 57 51 54 53
Eli Lilly & Co. 93 92 93 99 99 97 90 89 92 103 80 97 93 93 99 88 84 80 79
Johnson & Johnson 70 71 67 67 70 72 65 61 67 67 64 64 62 68 65 62 60 62 60
Merck & Co. Inc. 69 69 68 66 69 68 62 58 66 68 68 63 64 69 66 58 59 62 66
Pfizer Inc. 81 72 73 69 83 69 69 66 87 74 72 69 58 48 48 40 59 55 52
Regeneron Pharmaceuticals Inc. 164 154 140 146 146 144 144 160 161 155 146 158 156 148 151 160 148 132 107
Thermo Fisher Scientific Inc. 74 74 74 73 74 73 72 70 71 68 68 70 70 67 66 66 63 66 70
Vertex Pharmaceuticals Inc. 65 62 60 62 61 61 59 53 60 58 64 58 58 60 61 59 58 58 59

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 6.14 = 59

2 Click competitor name to see calculations.


The analysis of short-term operating activity reveals a fluctuating trend in the efficiency of receivable collections from March 2022 through September 2026. The data indicates a period of initial deterioration in collection efficiency followed by cycles of recovery and stabilization.

Receivables Turnover
A downward trajectory is observed during 2022, with the ratio declining from 7.18 in March to a low of 5.65 by December. Subsequently, the ratio experienced moderate volatility, reaching a peak of 6.51 in December 2023. From 2024 through 2026, the turnover ratio remained relatively stable, fluctuating within a narrow band between 5.60 and 6.17, ending the period at 6.14.
Average Receivable Collection Period
The collection period exhibits an inverse relationship with the turnover ratio, characterized by an overall increase in the time required to convert receivables into cash. The period expanded from 51 days in March 2022 to a peak of 65 days by December 2022. While efficiency improved during 2023 and early 2024—reaching a minimum of 56 days—a secondary peak of 65 days occurred in June 2025. The period concluded at 59 days in September 2026.

Overall, the operating activity patterns suggest a shift in the credit cycle. While the company managed to recover some efficiency after the late 2022 peak, the average collection period has generally settled at a higher level than the initial 51-day baseline, indicating a slightly longer average duration for payment receipts.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Operating Cycle

Gilead Sciences Inc., operating cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period 111 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Average receivable collection period 59 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Short-term Activity Ratio
Operating cycle1 170 177 173 166 170 169 159 156 160 172 164 163 169 163 159 162 137 136 132
Benchmarks
Operating Cycle, Competitors2
AbbVie Inc. 187 180 173 174 178 186 177 161 164 153 155 148 153 160 155 146 134 145 143
Amgen Inc. 308 298 285 288 280 289 286 276 295 343 409 510 347 349 363 363 351 339 323
Danaher Corp. 167 172 150 148 155 155 150 142 155 153 150 156 163 157 157 148 147 152 147
Eli Lilly & Co. 562 555 521 553 540 532 469 418 441 419 392 395 354 360 367 325 280 284 268
Johnson & Johnson 244 247 239 238 246 240 228 226 236 233 222 218 211 232 220 209 196 198 192
Merck & Co. Inc. 187 195 206 214 229 230 212 205 215 221 219 207 203 206 200 182 177 181 199
Pfizer Inc. 297 284 305 311 334 308 298 288 306 252 242 218 196 206 167 135 160 155 151
Regeneron Pharmaceuticals Inc. 603 633 631 702 717 714 726 732 734 717 699 677 664 680 700 722 588 511 394
Thermo Fisher Scientific Inc. 148 149 149 148 156 153 148 142 150 144 142 142 146 146 145 145 148 157 164
Vertex Pharmaceuticals Inc. 502 427 444 435 430 406 379 340 327 296 286 272 271 252 238 215 194 193 188

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= 111 + 59 = 170

2 Click competitor name to see calculations.


The analysis of the operating activity ratios reveals a consistent expansion of the operating cycle over the period from March 2022 to September 2026. The duration required to convert inventory and receivables into cash has increased, primarily driven by a lengthening inventory processing period.

Average Inventory Processing Period
A sustained upward trend is observed in the time required to process inventory. Starting at 81 days in March 2022, the period experienced a gradual increase, surpassing 100 days by March 2023 and reaching a peak of 115 days by June 2026. This indicates a deceleration in inventory turnover or a strategic increase in stock holdings over the observed timeframe.
Average Receivable Collection Period
The collection period exhibits relative stability compared to inventory processing, despite a moderate increase from the initial 51 days in March 2022. While fluctuations occur, the period generally remained within a range of 56 to 65 days for the majority of the analyzed period, suggesting a consistent efficiency in the credit and collection processes.
Operating Cycle
The total operating cycle reflects the combined impact of inventory and receivable periods, showing a clear trajectory of growth. The cycle expanded from 132 days in March 2022 to 170 days by September 2026, with a notable increase occurring between September and December 2022. The overall lengthening of the cycle is predominantly attributable to the increase in the average inventory processing period, which has outweighed the relative stability of receivable collection times.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Average Payables Payment Period

Gilead Sciences Inc., average payables payment period calculation (quarterly data)

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Payables turnover 6.66 9.22 9.52 8.72 7.66 10.65 8.47 7.50 7.49 12.57 10.69 11.81 9.90 9.06 8.99 6.25 11.22 11.89 11.43
Short-term Activity Ratio (no. days)
Average payables payment period1 55 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Benchmarks (no. days)
Average Payables Payment Period, Competitors2
Amgen Inc. 95 90 91 72 85 89 70 54 61 73 60 69 70 64 73 90 69 72 78
Bristol-Myers Squibb Co. 110 103 108 94 107 140 104 94 106 120 117 111 97 108 114 109 96 107 112
Danaher Corp. 60 64 64 67 63 65 66 66 60 63 62 65 65 63 64 67 65 73 72
Eli Lilly & Co. 149 169 148 178 154 161 140 140 135 142 127 134 130 138 119 106 86 87 70
Johnson & Johnson 106 107 123 145 119 119 123 137 120 121 113 132 111 133 120 137 118 116 112
Merck & Co. Inc. 96 78 82 98 103 95 92 98 86 83 81 89 80 80 84 89 71 75 86
Pfizer Inc. 88 98 98 119 110 106 110 115 99 79 87 98 72 93 76 72 66 59 55
Regeneron Pharmaceuticals Inc. 173 180 163 163 158 129 129 146 94 110 137 122 106 116 136 138 98 91 68
Thermo Fisher Scientific Inc. 40 43 46 50 44 43 44 45 38 37 37 41 35 34 39 48 37 41 46
Vertex Pharmaceuticals Inc. 92 89 106 102 95 102 105 98 98 85 96 106 117 115 107 103 44 73 66

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 6.66 = 55

2 Click competitor name to see calculations.


An analysis of the short-term operating activity ratios reveals significant volatility in the management of accounts payable over the observed period. The average payables payment period exhibits a non-linear trend characterized by periodic spikes and subsequent contractions, which is mirrored inversely by the payables turnover ratio.

Average Payables Payment Period Dynamics
The payment period fluctuated between a minimum of 29 days in June 2024 and a maximum of 58 days in December 2022. Notable expansions in the duration of payment are observed in December 2022 (58 days), September 2024 (49 days), and September 2026 (55 days), suggesting intermittent extensions of credit terms with suppliers or strategic shifts in cash outflow timing.
Payables Turnover Correlations
The payables turnover ratio maintains a strict inverse relationship with the payment period. Peak efficiency in turnover was recorded in June 2024 at 12.57, which coincides with the shortest recorded payment window. The lowest turnover rates occurred in December 2022 (6.25) and September 2026 (6.66), reflecting periods where obligations were settled at a slower velocity.
Temporal Patterns and Trends
A pattern of cyclical volatility is evident. Following a period of relative stability in early 2022, a sharp increase in the payment period occurred in late 2022, followed by a steady decline from March 2023 through December 2023, where the period dropped from 41 to 31 days. A similar sequence of contraction and expansion is observed between 2024 and 2026, with the payment period frequently oscillating between 30 and 50 days.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?


Cash Conversion Cycle

Gilead Sciences Inc., cash conversion cycle calculation (quarterly data)

No. days

Microsoft Excel
Sep 30, 2026 Jun 30, 2026 Mar 31, 2026 Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022
Selected Financial Data
Average inventory processing period 111 115 114 104 105 108 103 100 101 110 102 100 105 106 102 97 78 81 81
Average receivable collection period 59 62 59 62 65 61 56 56 59 62 62 63 64 57 57 65 59 55 51
Average payables payment period 55 40 38 42 48 34 43 49 49 29 34 31 37 40 41 58 33 31 32
Short-term Activity Ratio
Cash conversion cycle1 115 137 135 124 122 135 116 107 111 143 130 132 132 123 118 104 104 105 100
Benchmarks
Cash Conversion Cycle, Competitors2
Amgen Inc. 213 208 194 216 195 200 216 222 234 270 349 441 277 285 290 273 282 267 245
Danaher Corp. 107 108 86 81 92 90 84 76 95 90 88 91 98 94 93 81 82 79 75
Eli Lilly & Co. 413 386 373 375 386 371 329 278 306 277 265 261 224 222 248 219 194 197 198
Johnson & Johnson 138 140 116 93 127 121 105 89 116 112 109 86 100 99 100 72 78 82 80
Merck & Co. Inc. 91 117 124 116 126 135 120 107 129 138 138 118 123 126 116 93 106 106 113
Pfizer Inc. 209 186 207 192 224 202 188 173 207 173 155 120 124 113 91 63 94 96 96
Regeneron Pharmaceuticals Inc. 430 453 468 539 559 585 597 586 640 607 562 555 558 564 564 584 490 420 326
Thermo Fisher Scientific Inc. 108 106 103 98 112 110 104 97 112 107 105 101 111 112 106 97 111 116 118
Vertex Pharmaceuticals Inc. 410 338 338 333 335 304 274 242 229 211 190 166 154 137 131 112 150 120 122

Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).

1 Q3 2026 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= 111 + 59 – 55 = 115

2 Click competitor name to see calculations.


The Cash Conversion Cycle exhibits a general expansion from early 2022 through late 2026, indicating a prolonged duration between the initial outlay of cash for inventory and the final receipt of cash from sales. While the cycle began at 100 days in March 2022, it reached a peak of 143 days in June 2024 before concluding at 115 days by September 2026.

Average Inventory Processing Period
A consistent upward trajectory is observed in inventory management. The processing period rose from 81 days in the first half of 2022 to a peak of 115 days in June 2026. This persistent increase suggests a slowing of inventory turnover, which may be attributed to strategic stockpiling or a decrease in sales velocity relative to inventory holdings.
Average Receivable Collection Period
Receivable collections remained relatively stable, though they shifted slightly higher over the observed period. After an initial low of 51 days in March 2022, the period fluctuated primarily between 56 and 65 days. This stability indicates a consistent application of credit policies and a steady rate of collection efficiency.
Average Payables Payment Period
Payment to suppliers is characterized by significant volatility. The period experienced sharp fluctuations, dropping to 29 days in June 2024 and spiking to 58 days in December 2022 and 55 days in September 2026. These oscillations suggest inconsistent timing in supplier payments or an opportunistic approach to managing short-term liabilities.

The overall lengthening of the cash conversion cycle is primarily driven by the increase in the inventory processing period, which has offset the benefits of occasional extensions in the payables payment period. Although the cycle contracted slightly in the final quarters of 2026, the operational efficiency regarding cash recovery remains lower than the levels observed at the start of 2022.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.

How can I help you?